Studies in human subjects have identified increased FGF-21 levels in cardiometabolic pathologies such as non-alcoholic fatty liver disease, coronary artery disease, diastolic heart failure, diabetes, and insulin resistance, mediating the adaptive response to various stresses [33]. This evidence concerns the gene FGF21 and diastolic heart failure.